chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Shortly after vaccines given, patient became pale, diaphoretic and passes out. Ammonia inhalant used and patient aroused. A and O. C/o nausea, dizzy, lightheaded. Cool compress applied. Mother present. Patient observed x 20 minutes without further issues. Denied issues upon leaving. States, "I am just tired". Did drink water.
This case was reported by a other health professional via call center representative and described the occurrence of hives in a female patient who received HAVRIX (batch number 5D952, expiry date 20th April 2018). Concurrent medical conditions included milk allergy. On an unknown date, the patient received HAVRIX. On an unknown date, an unknown time after receiving HAVRIX, the patient experienced hives and allergic reaction. On an unknown date, the outcome of the hives and allergic reaction were unknown. It was unknown if the reporter considered the hives and allergic reaction to be related to HAVRIX. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional reported that the patient experienced hives, described as an allergic reaction, after receiving a dose of HAVRIX. The reaction was further described as similar to the reaction the patient had after consuming milk. The reporter had limited information but consented to follow up by email.
Localized erythema at the site of injection that progressed to diffuse urticarial rash, all starting about 4-5 days after vaccine administration.
No adverse event from invalid pediatric dose of Hep A vaccine, no treatment required. Patient was 19 y/o
fever; chills; body aches; headache; This is a spontaneous report from a contactable consumer or other non Healthcare Professional (patient, reported for self). A 46-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH mRNA COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number and Expiration date: Not reported), via an unspecified route of administration on 08Mar2021 as dose 1, single for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. Patient reported that one week after the administration of the first dose, the patient experienced fever, chills, body aches, headache on unspecified date and enquired how long the adverse events would last. Response was give from the overall safety summary. It was unknown whether the patient got an admission to the hospital due to event. It was unknown if the patient received any treatment. Outcome of the events was unknown.  Information on the lot/batch number has been requested.  Follow-up attempts are completed. No further information is expected.
On 19-JUN-2013 the patient was vaccinated with GARDASIL (lot number 0420AE and expiration date: 01-DEC-2014), first dose, in the left deltoid (concentration and duration was not reported). There was also reported that patient had an unspecified birth control as a concomitant medication. No other concomitant medications were reported. On 19-JUN-2013 the patient experienced soreness at the injection site which lasted for two days and then resolved. The patient also reported that 30 minutes after the injection she experienced pain in the right upper arm and had a hard time grasping and lifting objects with the right arm. The patient reported that this lasted for a few days, then resolved on an unspecified date and she was unmotivated and fatigued for one month after the injection which at this point was also resolved and did not receive treatment for the event. There were no laboratories performed. The outcome of unmotivated, fatigued, soreness at the injection site, pain in the right upper arm and hard time grasping and lifting objects was reported as recovered/resolved. Causality between Adverse events and GARDASIL was not reported. Additional information has been requested.
7/24/14 - warmth, redness, and swelling approximately 50mm in diameter at injection site, slight itching, and tender to touch. (Redness and swelling have completely resolved 7/30/14).
very tired; headache; This spontaneous case was reported by an other health care professional and describes the occurrence of FATIGUE (very tired) and HEADACHE (headache) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (very tired) and HEADACHE (headache). At the time of the report, FATIGUE (very tired) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment information was unknown. This spontaneous case was reported by an other health care professional and describes the occurrence of FATIGUE (very tired) and HEADACHE (headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced FATIGUE (very tired) and HEADACHE (headache). At the time of the report, FATIGUE (very tired) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. Treatment information was unknown.
Around 10PM started feeling feverish, ache throughout my body, tired, inability to rest and sleep and soreness at injection site. It's now 11:45 and still feeling the same.
After the 15 minute mandatory wait she had a reaction. She stated that her blood pressure was high (141/100) (79). And that her arm was hot, numb and had the feeling of "pins and needles".
Team member began to feel like her heart was racing.   12/29 at 08:58 Am VS:  BP 151/102; HR120; Sat. 100% We monitored symptoms and VS until 10:41 AM  VS:  BP 101/57; HR 99 We took her to the ED for further evaluation
Mild muscle pain, tenderness. Red blotchy area near deltoid and to underside of arm.
itchy rash on face; felt cold; This case was reported by a consumer via call center representative and described the occurrence of feeling cold in a 82-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th June 2019, the patient received Shingrix (intramuscular). On 11th June 2019, 1 days after receiving Shingrix, the patient experienced feeling cold. On 15th June 2019, the patient experienced itchy rash. On an unknown date, the outcome of the feeling cold was recovered/resolved and the outcome of the itchy rash was not recovered/not resolved.   It was unknown if the reporter considered the feeling cold and itchy rash to be related to Shingrix.  Additional details were provided as follows: The next day of vaccination, the patient felt very cold even though it was a warm day. Five days after receiving Shingrix, the patient developed an itchy rash on her face. The reporter consented to follow up
Dizziness onset approximately 16 hours post administration typically when laying down and turning over in bed as well as standing up after laying down.  Sometimes randomly when sitting.
SEVERE HEADACHE; This spontaneous report received from a patient concerned a 35 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included: alcohol user, and non-smoker, and other pre-existing medical conditions included: The patient was not pregnant at the time of reporting .The patient had no drug abuse or illicit drug usage. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, intramuscular, batch number: Unknown) dose was not reported, administered on 22-APR-2021 for prophylactic vaccination.The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On 25-OCT-2021, the patient experienced severe headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of severe headache was not reported. This report was non-serious.
pt devel stools w/a medicinal smell & a different color than usual p/vax;
FEEL LUMP; LYMPH NODES (BREAST TISSUE AND ARMPIT SWOLLEN); SWELLING MOVED TO SIDE OF BREAST TISSUE (SWOLLEN ARMPIT) AND FELT HEAT UNDER ARMPIT; BODY ACHE; JOINT ACHE; MUSCLE ACHE; SWELLING ON ARM WHERE INJECTION WAS GIVEN; INJECTION SITE HEAT; This spontaneous report received from a patient concerned a 55 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included rheumatoid arthritis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802070) dose was not reported, administered on 14-MAR-2021 for prophylactic vaccination at her right arm. No concomitant medications were reported. On 14-MAR-2021, the subject experienced swelling moved to side of breast tissue (swollen armpit) and felt heat under armpit. On 14-MAR-2021, the subject experienced body ache. On 14-MAR-2021, the subject experienced joint ache. On 14-MAR-2021, the subject experienced muscle ache. On 14-MAR-2021, the subject experienced swelling on arm where injection was given. On 14-MAR-2021, the subject experienced injection site heat. On an unspecified date, the subject experienced feel lump, and lymph nodes (breast tissue and armpit swollen). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body ache, joint ache, muscle ache, swelling on arm where injection was given, and injection site heat, had not recovered from swelling moved to side of breast tissue (swollen armpit) and felt heat under armpit, and the outcome of feel lump and lymph nodes (breast tissue and armpit swollen) was not reported. This report was non-serious.; Sender's Comments: V0:Medical assessment comment not required as per standard procedure as case assessed as non serious.
Approximately 15 minutes after receiving the vaccine the patient reported feeling lightheaded. Patient reported no vision changes, no problems breathing or talking. She said she does not like needles and that could have been the issue. I asked her to remain seated in observation and got her a cup of water. She drank with no problems swallowing. Reported no other symptoms. After approximately 5 minutes patient reported feeling about the same. After an additional approximate 5 minutes patient reported feeling much better. She remained in observation for approximately 5 more minutes, totaling approximately 30 minutes and reported feeling good. I offered for her to remain in observation as she felt comfortable but at that point she said she felt good and would call the pharmacy with any questions or concerns.
This case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a male patient who received SHINGRIX for prophylaxis. In March 2019, the patient received SHINGRIX. In March 2019, less than a day after receiving SHINGRIX, the patient experienced influenza-like symptoms. On an unknown date, the outcome of the influenza-like symptoms was not recovered/not resolved. It was unknown if the reporter considered the influenza-like symptoms to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient received the vaccine 4 days before the date of reporting, almost exactly 96 hours, developed flu-like symptoms that evening, but the patient expected those to resolve by now. The patient still felt like he had influenza.
I had that 'jolting thing' (not clarified) take my breath away; I can't move, the pain was in my thoracic; I can't move, the pain was in my thoracic; back injury is in my thoracic; but there was increased swelling in my arm, bigger than a baseball.; my entire body had tingling; numbness; I had intense fatigue; flu like symptoms; had a fever; I was sweating; This is a spontaneous report from a contactable consumer (patient). A female patient of unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-119 VACCINE, Solution for injection, Lot number: ER8730) via unknown route of administration on 27Mar2021 as dose 2 single for COVID-19 immunisation. Medical history included cancer (on the righthand side ovary with the appendix removed), low immune system, respiratory and pulmonary issues, neural issues, ongoing allergy, fractured hand, vision disability. Concomitant medications included loratadine for allergy, montelukast for allergy, colecalciferol (VITAMIN D3), primidone, salbutamol (VENTOLINE). The patient previously took first dose of BNT162B2 (PFIZER-BIONTECH COVID-119 VACCINE) on 05Mar2021 for COVID-19 immunization and experienced sciatic nerve back pain (back inherent disabilities), could not move, could not walk, could not sit, could not lay down, could not breathe it caused pain, I have essential tremors, headache, rash (on my face for three days and my arm), swollen up, dizzy (to the point where I almost fell four times). It was reported that after the second dose, I had that 'jolting thing' (not clarified) take my breath away. I can't move, the pain was in my thoracic. My back injury was in my thoracic. Again, took the medicine that the doctor prescribed for me and that went away but there was increased swelling in my arm, bigger than a baseball. An allergy medicine took care of that. There was, the whole thing that I told you about was normal symptoms but they didn't really quite severe as just before the back pain came on, my entire body had tingling, numbness. And I didn't have headache this time but in addition to the back and the numbness and the swelling, I had intense fatigue, flu like symptoms. I had a fever that took two days to break even with Motrin and was so bad, I mean, I was sweating all on 27Mar2021. I am a cancer patient, happens to be the cancer that I had was on the right-hand side ovary with the appendix removed." The outcome of events was unknown.  No follow-up attempts are needed. No further information is required.
Injection site red and swollen. Raised about size of half dollar. Started 4/16/03 and still present.
A report was received from a health care professinal on 12/8/03 concerning a 3 and a half year old male vaccinee who inadvertently received Fluvirin instead of Fluzone on the same day. On 12/8/03, the vaccinee inadvertently received Fluvirin instead of Fluzone. At the time of the report, no adverse events had been reported. There was insufficient information to determine the reporter's causality assessment. Update 2/9/04: A follow up report was received from a health care professional indicating that the vaccinee had experienced no adverse events. The vaccinee received Fluzone on 12/22/03. No follow up pending, all information received.
Information has been received from a physician concerning a 14 year old female patient with a history of seizure and migraines who on 13-AUG-2010 was vaccinated intramuscularly with her 0.5 cc first dose of GARDASIL (Lot # 08872-not valid as reported- and expire date in October 2014). The physician stated that after the first shot the patient fainted and on approximately 20-AUG-2010 "one week later", she noticed a lump above her clavicle and discomfort under her arm. The patient sought unspecified medical attention. At the time of report, the patient was recovering from fainted, lump above her clavicle and discomfort under her arm. Follow-up information was received concerning a current 14 year female with no pre-existing allergies, birth defects or medical conditions and no illness at the time of vaccination who on 13-AUG-2010 at 12:30 PM was vaccinated intramuscularly with her first dose of GARDASIL. On 13-AUG-2010 the patient was feeling OK, she was walking out of room and started feeling faint and seeing black. The patient was taken into room and laid her down legs up. Pulse, blood pressure and temperature measurement were performed with no results provided. Before the patient left the physician discharged her in stable condition. Patient later came back with a lymph gland above left clavicle and sore on the left shoulder. At the time of report, the patient's lymph gland above left clavicle and sore on the left shoulder outcome was unknown. On follow up information received on 14-DEC-2010 the medical assistant reported that the patient was seen at the office on 23-AUG-2010 for her lump above her clavicle and also because she was experiencing headaches. At the time of the report, the patient continued to have headaches so the physician might refer her to a specialist. Follow-up information was received, was reported that on unspecified date experienced regional lymph node reaction and possible migraine headache. At the time of the report the patient had recovered from regional lymph node reaction and possible migraine headache. The patient did not seek medical attention. Additional information is not expected.
I started itching on my hands and arms. Then I started getting hives. The itching and hives spread quickly to my entire body. I had some swelling in my right arm. I took 2 Benadryl almost immediately. Symptoms started improving slightly in about an hour. Symptoms were completely gone by about 8:00 PM.
developed breast pain in july 2019.   reports other individuals traveling who had received similar vaccines had also developed breast pain or neck pain after vaccines.
Extreme muscle and joint pain.  Also pain at injection site.  Fatigue and balance issues.
Flushing/sweating, fatigue. BP 152/89 (pulse 74), then 145/87.
24 hrs headache nausea, fever, chills. (Took Motrin 400mg) 5 days later severe itchiness from head to toe. (Took antihistamine xyzal)
itchiness, abdominal cramping for 5 days (2 days after vaccine received) Itching at site of injection  x 1 day reported on 1/14/2021 redness, swelling and injection site pain x 3 days
This case was reported by a healthcare professional and described the occurrence of injection site induration in a 53-year-old female subject who was vaccinated with ENGERIX B (GlaxoSmithKline). Concurrent medications included ADDERALL. On 25 August 2010 the subject received 1st dose of ENGERIX B (20 mcg, unknown, right arm). On 25 August 2010, less than one day after vaccination with ENGERIX B, the subject experienced injection site induration, further described as a hard nodule at the injection site that was tender to the touch. The subject was treated with warm compresses. No other symptoms were reported. At the time of reporting the injection site induration was unresolved. The healthcare professional considered the event was probably related to vaccination with ENGERIX B.
Swelling of throat, hives, itching, severe intestinal pain, diarrhea, profuse sweating, redness of skin on entire body, wheezing, tingling and numbness of hands and feet. Epinephrine and Benadryl administered. Pain and diarrhea for 48 hours.
Asthmatic Attack; This spontaneous case was reported by a consumer and describes the occurrence of ASTHMA (Asthmatic Attack) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     The patient's past medical history included Asthma since an unknown date. Concomitant products included Asthma Inhaler for Asthma, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE, VILANTEROL TRIFENATATE (TRELEGY), ANTIDEPRESSANTS and VITAMINS NOS for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Feb-2021, the patient experienced ASTHMA (Asthmatic Attack). At the time of the report, ASTHMA (Asthmatic Attack) was resolving. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment included Steroid pill 4 mg and levofloxacin.
1) canker sores broke out in my mouth about 2 hours after receiving Covid - Moderna vaccine  2) 8 days after Moderna Covid vaccine a red, double circle rash broke out at injection site.  Looked like figure 8, each circle was the size of a quarter.  Rash was hot, and raised, not itchy. Treated with Claritin, rash was gone in next 24 hours.
Has a severe cough; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Has a severe cough) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COUGH (Has a severe cough). At the time of the report, COUGH (Has a severe cough) outcome was unknown.            No concomitant medications were mentioned. No treatment details were reported.   This case was linked to MOD-2022-440015 (Patient Link).
This spontaneous report was received from a registered nurse and refers to the multiple unspecified patients of unknown age and gender. No information on the patients' concomitant medications, concurrent conditions, pertinent medical history, drug reactions or allergies was reported. On unknown dates, the patients were vaccinated with improperly stored doses of VARIVAX (lot # M023382 with expiration date on 11-MAY-2018 and lot # M010483 with expiration date on 01-MAR-2018; dose and route of administration were unknown), for prophylaxis. The vaccines were exposed to temperature excursion of 5.5 degrees Fahrenheit for 4 hours and 45 minutes and 24.8 degrees Fahrenheit for 15 hours and 40 minutes. There were no previous temperature excursions. Data logger was involved. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Follow up information has been received on 22-NOV-2016. A message was left requiring a return call from the nurse and a request was made for the patients' identifiers and dates of vaccinations. All telephone attempts to obtain follow up information had been unsuccessful. Additional information has been requested.; Sender's Comments:  US-009507513-1610USA003925: US-009507513-1610USA004869:, MERCK 1610USA004868:Mfr number.
Information has been received from a healthcare worker (immunization official) referring to a 4 year old patient of unknown gender. The patient's medical history, concurrent condition and concomitant therapy were not reported. On 27-JUL-2015, the patient was vaccinated with a dose of VARIVAX (Merck), lot # K010440 (expiration date, dose and route not reported), which was improperly stored. No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.